The Dose and Duration-dependent Association between Melatonin Treatment and Overall Cognition in Alzheimer's Dementia: A Network Meta- Analysis of Randomized Placebo-Controlled Trials
Journal
Current neuropharmacology
Journal Volume
20
Journal Issue
10
Pages
1816
Date Issued
2022
Author(s)
Tseng, Ping-Tao
Zeng, Bing-Yan
Chen, Yen-Wen
Yang, Chun-Pai
Su, Kuan-Pin
Chen, Tien-Yu
Wu, Yi-Cheng
Lin, Pao-Yen
Carvalho, Andre F
Stubbs, Brendon
Matsuoka, Yutaka J
Li, Dian-Jeng
Liang, Chih-Sung
Hsu, Chih-Wei
Sun, Cheuk-Kwan
Cheng, Yu-Shian
Yeh, Pin-Yang
Shiue, Yow-Ling
Abstract
While Alzheimer's dementia (AD) has a prevalence as high as 3-32% and is associated with cognitive dysfunction and the risk of institutionalization, no efficacious and acceptable treatments can modify the course of cognitive decline in AD. Potential benefits of exogenous melatonin for cognition have been divergent across trials.
Subjects
Alzheimer’s dementia; circadian rhythm; cognition; dementia; melatonin; network meta-analysis; psychiatry; quality of life
Publisher
BENTHAM SCIENCE PUBL LTD